SoC Tx Advanced SCLC Module

CME

Standard-of-Care Therapy in Advanced SCLC

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 29, 2024

Expiration: March 28, 2025

Carl M. Gay
Carl M. Gay, MD, PhD

Activity

Progress
1 2
Course Completed

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: small cell lung cancer. v.2.2024. nccn.org. Accessed March 20, 2024.
  2. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.
  3. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
  4. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408.
  5. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.
  6. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021. Abstract LBA61.
  7. Liu S. Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA01.04.
  8. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658-6567.
  9. Eckardt JR, von Pawel J, Pujol J-L, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086-2092.
  10. Sands J, Subramanian J. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting. Front Oncol. 2023;13:1161931.
  11. Baize N, Monnet I, Greillier L, et al. Carboplain plus etoposide versus topotecan as second-line treatment for patients with sensitive relapse small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2020;21:1224-1233.
  12. Trabectedin. [prescribing information]. Horsham, PA: Janssen pharmaceuticals; 2020.
  13. Patel S, Petty WJ, Sands JM. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211020529.
  14. Santamaría Nuñez G, Robles CM, Giraudon C, et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther. 2016;15:2399-2412.
  15. Bian X, Lin W. Targeting DNA replication stress and DNA double-strand break repair for optimizing SCLC treatment. Cancer (Basel). 2019;11:1289.
  16. Belgiovine C, Bello E, Liguori M, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117:628-638.
  17. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-654.
  18. Lurbinectedin. [prescribing information]; Palo Alto, CA: Jazz Pharmaceuticals; 2023.
  19. Subbiah V, Paz-Ares L, Besse B, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020;150:90-96.
  20. Atezolizumab [prescribing information]. South San Francisco, CA: Genentech; 2018.
  21. Yang F, Wang JF, Wan Y, et al. Comparative analysis of predictive biomarkers for PD-1/PD-L1 inhibitors in cancers: developments and challenges. Cancers (Basel). 2022;14:109.
  22. Zhu L, Qin J. Predictive biomarkers for immunotherapy response in extensive-stage SCLC. J Cancer Res Clin Oncol. 2024;150:22.
  23. Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3.
  24. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.e347.
  25. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526-1537.
  26. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063-2075.
  27. Wermke M. Phase I dose escalation trial of the DLL3/CD3 Igg-like T cell engager BI 764532 in patients with DLL3+ tumors: focus on SCLC. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA01.05.
  28. Johnson M, Awad M, Koyama T, et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1/2 study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.05.
  29. Dowlati A, Cervantes A, Babu S, et al. Sacituzumab govitecan as second-line treatment for extensive stage small cell lung cancer. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract 199MO.
  30. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7:69-79.
  31. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664-672.
  32. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663-671.
  33. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36-42.